A review of human vaccine research and development: Malaria

被引:99
作者
Girard, Marc P.
Reed, Zarifah H.
Friede, Martin
Kieny, Marie Paule
机构
[1] Univ Paris 07, FR-69008 Lyon, France
[2] WHO, Initiat Vaccine Res, CH-1211 Geneva 27, Switzerland
基金
英国惠康基金; 美国国家卫生研究院;
关键词
plasmodium; vaccine; clinical trials; Africa; sporozoites; merozones;
D O I
10.1016/j.vaccine.2006.09.074
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The last several years have seen significant progress in the development of vaccines against malaria. Most recently, proof-of-concept of vaccine-induced protection from malaria infection and disease was demonstrated in African children. Pursued by various groups and on many fronts, several other candidate vaccines are in early clinical trials. Yet, despite the optimism and promise, an effective malaria vaccine is not yet available, in part because of the lack of understanding of the types of immune responses needed for protection, added to the difficulty of identifying, selecting and producing the appropriate protective antigens from a parasite with a genome of well over five thousand genes and to the frequent need to enhance the immunogenicity of purified antigens through the use of novel adjuvants or delivery systems. Insufficient clinical trial capacity and normative research functions Such as local ethical committee reviews also contribute to slow down the development process. This article attempts to summarize the state of the art of malaria vaccine development. (c) 2006 World Health Organization. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1567 / 1580
页数:14
相关论文
共 166 条
[1]   High-throughput generation of P. falciparum functional molecules by recombinational cloning [J].
Aguiar, JC ;
LaBaer, J ;
Blair, PL ;
Shamailova, VY ;
Koundinya, M ;
Russell, JA ;
Huang, FY ;
Mar, W ;
Anthony, RM ;
Witney, A ;
Caruana, SR ;
Brizuela, L ;
Sacci, JB ;
Hoffman, SL ;
Carucci, DJ .
GENOME RESEARCH, 2004, 14 (10B) :2076-2082
[2]  
AHUJA S, 2006, VACCINE
[3]   Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3 [J].
Aidoo, M ;
Lalvani, A ;
Gilbert, SC ;
Hu, JT ;
Daubersies, P ;
Hurt, N ;
Whittle, HC ;
Druihle, P ;
Hill, AVS .
INFECTION AND IMMUNITY, 2000, 68 (01) :227-232
[4]  
Alonso PL, 2006, INT MICROBIOL, V9, P83
[5]   Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum [J].
Alonso, PL ;
Smith, TA ;
ArmstrongSchellenberg, JRM ;
Kitua, AY ;
Masanja, H ;
Hayes, R ;
Hurt, N ;
Font, F ;
Menendez, C ;
Kilama, WL ;
Tanner, M .
JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (02) :367-372
[6]   Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children:: single-blind extended follow-up of a randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Aide, P ;
Sigauque, B ;
Milman, J ;
Mandomando, I ;
Bassat, Q ;
Guinovart, C ;
Espasa, M ;
Corachan, S ;
Lievens, M ;
Navia, MM ;
Dubois, MC ;
Menendez, C ;
Dubovsky, F ;
Cohen, J ;
Thompson, R ;
Ballou, WR .
LANCET, 2005, 366 (9502) :2012-2018
[7]   Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Milman, J ;
Mandomando, I ;
Spiessens, B ;
Guinovart, C ;
Espasa, M ;
Bassat, Q ;
Aide, P ;
Ofori-Anyinam, O ;
Navia, MM ;
Corachan, S ;
Ceuppens, M ;
Dubois, MC ;
Demoitié, MA ;
Dubovsky, F ;
Menéndez, C ;
Tornieporth, N ;
Ballou, WR ;
Thompson, R ;
Cohen, J .
LANCET, 2004, 364 (9443) :1411-1420
[8]   RANDOMIZED TRIAL OF EFFICACY OF SPF66 VACCINE AGAINST PLASMODIUM-FALCIPARUM MALARIA IN CHILDREN IN SOUTHERN TANZANIA [J].
ALONSO, PL ;
SMITH, T ;
SCHELLENBERG, JRMA ;
MASANJA, H ;
MWANKUSYE, S ;
URASSA, H ;
DEAZEVEDO, IB ;
CHONGELA, J ;
KOBERO, S ;
MENENDEZ, C ;
HURT, N ;
THOMAS, MC ;
LYIMO, E ;
WEISS, NA ;
HAYES, R ;
KITUA, AY ;
LOPEZ, MC ;
KILAMA, WL ;
TEUSCHER, T ;
TANNER, M .
LANCET, 1994, 344 (8931) :1175-1181
[9]   Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi [J].
Anders, RF ;
Crewther, PE ;
Edwards, S ;
Margetts, M ;
Matthew, MLSM ;
Pollock, B ;
Pye, D .
VACCINE, 1998, 16 (2-3) :240-247
[10]   Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum [J].
Arakawa, T ;
Komesu, A ;
Otsuki, H ;
Sattabongkot, J ;
Udomsangpetch, R ;
Matsumoto, Y ;
Tsuji, N ;
Wu, YM ;
Torii, M ;
Tsuboi, T .
INFECTION AND IMMUNITY, 2005, 73 (11) :7375-7380